EagleClaw Capital Managment LLC Cuts Holdings in Gilead Sciences, Inc. $GILD

EagleClaw Capital Managment LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,590 shares of the biopharmaceutical company’s stock after selling 1,070 shares during the quarter. EagleClaw Capital Managment LLC’s holdings in Gilead Sciences were worth $952,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. GoalVest Advisory LLC boosted its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Activest Wealth Management lifted its stake in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new stake in Gilead Sciences during the second quarter worth about $27,000. Putney Financial Group LLC grew its position in Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the period. Finally, Colonial Trust Advisors grew its position in Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 213 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider owned 110,193 shares in the company, valued at approximately $13,011,589.44. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 71,500 shares of company stock valued at $8,336,040 in the last ninety days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $123.40 on Thursday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The business’s fifty day moving average price is $116.99 and its two-hundred day moving average price is $112.55. The stock has a market cap of $153.10 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $124.87.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the business earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Citigroup upped their target price on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $128.27.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.